Advertisement

European Journal of Epidemiology

, Volume 19, Issue 9, pp 871–875 | Cite as

High Seroprotection Rate Induced by Intradermal Administration of a Recombinant Hepatitis B Vaccine in Young Healthy Adults: Comparison with Standard Intramuscular Vaccination

  • Mohammad J. Ghabouli
  • Amir Hossein Sabouri
  • Naser Shoeibi
  • Sepideh Naghibzadeh Bajestan
  • H. Baradaran
Article

Abstract

Intradermal (ID) vaccination has been proposed as a cost-saving alternative for administration of Hepatitis B (HB) vaccine to implement of mass vaccination of high-risk groups, particularly in developing countries. Therefore, the effectiveness of ID vaccination needs to be evaluated and verified in different ethnic backgrounds. The present study is a randomized trail using a recombinant vaccine (Heberbiovac) to compare immunogenecity and safety of an intradermal low-dose (4 μg) with standard dose (20 μg) of intramuscular (IM) vaccination in healthy Iranian population. Participants were 143 healthy Iranian medical and nursing students randomly allocated to ID or IM vaccination group. The vaccine was inoculated at 0, 1 and 6months intervals. Serum samples were collected 1month after the last vaccination and the anti-HBs response was determined using ELISA. The overall seroprotection rate (anti-HBs level ≥ 10IU/L) was 97.3% for ID vaccination group, which was not different from that of IM vaccination group (98.55%)(p= 0.99). Similarly, geometric mean titers (GMT) of anti-HBs were not significantly different between ID (1164.1IU/L) and IM (1071.8IU/L) vaccination groups (p= 0.4). There was no significant difference in seroprotection rate and GMT of anti-HBs between sexes. Although induration and hyperpigmentation at the site of injection were more frequently observed in ID vaccination group, no other clinically adverse effects were observed in both vaccination groups. We conclude that the ID route, which would require one-fifth of the standard dose, would be suitable for use in certain groups such as high-risk adults when the cost of vaccine is the inhibiting factor for mass vaccination.

Hepatitis B vaccination Intradermal Intramuscular 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Farzadegan H, Shamszad M, Noori-Arya K. Epidemiology of viral hepatitis among Iranian population–a viral marker study. Ann Acad Med Singapore 1980; 9: 144-148.Google Scholar
  2. 2.
    Farhat A, Khademi G, Mazouman SJ. The prevalence of hepatitis B carrier state in Khorassan province of Iran. Saudi Med J 2003; 24: 549-551.Google Scholar
  3. 3.
    Deinhardt F, Zuckerman AJ. Immunization against hepatitis B: Report on a WHO meeting on viral hepatitis in Europe. J Med Virol 1985; 17: 209-217.Google Scholar
  4. 4.
    Kane MA. Status of hepatitis B immunization programmes in 1998. Vaccine 1998; 16(Suppl): S104-S108.Google Scholar
  5. 5.
    Rahman F, Dahmen A, Herzog-Hauff, S, Bocher WO, Galle PR, Lohr HF. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 2000; 31: 521-527.Google Scholar
  6. 6.
    Nothdurft HD, Dietrich M, Zuckerman JN, Knobloch J, Kern P, Vollmar J, Sanger R. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine 2002; 15; 20: 1157-1162.Google Scholar
  7. 7.
    Shokri F, Jafarzadeh A. High seroprotection rate induced by low doses of a recombinant hepatitis B vaccine in healthy Iranian neonates. Vaccine 2001; 14; 19: 4544-4548.Google Scholar
  8. 8.
    McLean AA, Hilleman MR, McAleer WJ, Buynak EB. Summary of worldwide clinical experience with H-B-Vax (B, MSD). J Infect 1983; 7(Suppl)1: 95-104.Google Scholar
  9. 9.
    Bryan JP, Sjogren MH, Perine PL, Legters LJ. Low-dose intradermal and intramuscular vaccination against hepatitis B. Clin Infect Dis 1992; 14: 697-707.Google Scholar
  10. 10.
    Hadler SC. Are booster doses of hepatitis B vaccine necessary? Ann Intern Med 1988; 108: 457-458.Google Scholar
  11. 11.
    Wainwright RB, McMahon BJ, Bulkow LR, Hall DB, Fitzgerald MA, Harpster AP, Hadler SC, Lanier AP, Heyward WL. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989; 28; 261: 2362-2366.Google Scholar
  12. 12.
    Poux JM, Ranger-Rogez S, Lagarde C, Benevent D, Denis F, Leroux-Robert C. Vaccination against hepatitis B virus. Value of intradermal administration in dialysed patients non responsive to intramuscular approach. Presse Med 1995; 6–13; 24(17): 803-806.Google Scholar
  13. 13.
    Prasetya E, Linggadjaja W, Syambali R, Kusumo S, Dharmesetyawan DF, Rahardja U. Intradermal vaccination against hepatitis B in Immanuel Hospital personnel–a preliminary report. Ann Acad Med Singapore 1986; 15: 153-157.Google Scholar
  14. 14.
    Struve J, Aronsson B, Frenning B, Forsgren M, Weiland O. Response to a booster dose 18 months after a low anti-HBs response (10–99 IU/L) to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine. Infection 1995; 23: 42-45.Google Scholar
  15. 15.
    Mok Q, Underhill G, Wonke B, Aldouri M, Kelsey M, Jefferies D. Intradermal hepatitis B vaccine in thalassaemia and sickle cell disease. Arch Dis Child 1989; 64: 535-540.Google Scholar
  16. 16.
    Yao FB, Li XX, Du YX, Ye SL. Combined intra-muscular–intradermal protocol of universal neonate HB vaccination irrespective of mother 's status of HBsAg. Vaccine 1998; 16: 586-589.Google Scholar
  17. 17.
    Coleman PJ, Shaw FE Jr, Serovich J, Hadler SC, Margolis HS. Intradermal hepatitis B vaccination in a large hospital employee population. Vaccine 1991; 9: 723-727.Google Scholar
  18. 18.
    Brink NS, Murray AB. Intradermal vaccination against hepatitis B in a group of medical students. S Afr Med J 1991; 1; 79: 653-654.Google Scholar
  19. 19.
    Herbert M, Butler AV, Roome AP, Caul EO. Comparison of intradermal and intramuscular hepatitis B vaccination in university students. Vaccine 1989; 7: 395-396.Google Scholar
  20. 20.
    Clarke JA, Hollinger FB, Lewis E, Russell LA, Miller CH, Huntley A, Flynn NM. Intradermal inoculation with Heptavax-B. Immune response and histologic evaluation of injection sites. JAMA 1989; 10; 262: 2567-2571.Google Scholar
  21. 21.
    Senden TF. Response to intradermal hepatitis B vaccination: Differences between males and females? Vaccine 1990; 8: 612-613.Google Scholar
  22. 22.
    Lankarani KB, Taghavi AR, Agah S, Karimi A. Comparison of intradermal and intramuscular administration of hepatitis B vaccine in neonates. Indian J Gastroenterol 2001; 20: 94-96.Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Mohammad J. Ghabouli
    • 1
  • Amir Hossein Sabouri
    • 2
    • 3
  • Naser Shoeibi
    • 4
  • Sepideh Naghibzadeh Bajestan
    • 3
  • H. Baradaran
    • 5
  1. 1.Department of Infectious DiseasesMashhad University of Medical SciencesMashhadIran
  2. 2.Department of ImmunologyMashhad University of Medical SciencesMashhadIran
  3. 3.Department of Neurology and GeriatricsKagoshima University Graduate School of Medical and Dental SciencesKagoshimaJapan; Phone:
  4. 4.Department of OphthalmologyMashhad University of Medical SciencesMashhadIran
  5. 5.Department of ImmunologyMashhad University of Medical SciencesMashhadIran

Personalised recommendations